AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biogen Inc. (BIIB)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

136.97

-0.36 (-0.26%)

At close: Feb 18, 2025, 3:59 PM

137.00

0.02%

After-hours: Feb 18, 2025, 06:54 PM EST

undefined% (undefined)

Bid	136
Market Cap	20.05B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	11.18
PE Ratio (ttm)	12.25
Forward PE	n/a
Analyst	Hold

Ask	137.5
Volume	861,726
Avg. Volume (20D)	1,473,410
Open	138.01
Previous Close	137.33
Day's Range	135.94 - 139.16
52-Week Range	128.51 - 238.00
Beta	undefined

About BIIB

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an ad...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Sep 17, 1991

Employees 7,605

Stock Exchange NASDAQ

Ticker Symbol BIIB

Website https://www.biogen.com

Full Company Profile

Analyst Forecast

According to 26 analyst ratings, the average rating for BIIB stock is "Hold." The 12-month stock price forecast is $210, which is an increase of 53.32% from the latest price.

Buy 46.15%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Biogen Inc. is scheduled to release its earnings on Apr 23, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

-4.28%

Biogen shares are trading lower after the company ... Unlock content with Pro Subscription

3 months ago

-1.28%

Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.

News

23 hours ago · marketwatch.com

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.

1 day ago · businesswire.com

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of ...

4 days ago · seekingalpha.com

Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma

Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mi...

6 days ago · benzinga.com

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.

5 days ago · benzinga.com

Biogen Analysts Lower Their Forecasts After Q4 Results

Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.

1 week ago · zacks.com

Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints

BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.

6 days ago · seekingalpha.com

Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript

Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Develo...

6 days ago · zacks.com

Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima...

6 days ago · zacks.com

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.

1 week ago · marketwatch.com

Biogen's stock hit by soft guidance and a decline in sales of MS drugs

Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.

Load More News